Main Article Content
The current COVID-19 pandemic challenges not only the lack of awareness of the disease, but also the rapid diagnosis, the prediction of severe early disease, the clinical characterization of mortality and severity of patients, and the effective management that affects the global scale, resulting in low capacities of healthcare systems, the resilience of systems and global economics. Therefore, early differential diagnosis and prediction of SARS-COV-2 infection severity are needed. CRP and NLR are diagnostic markers commonly used, most available, effective, and economically used primarily to evaluate the ongoing systemic inflammatory response.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
2. Wang P, Anderson N, Pan Y, et al. The SARS-CoV-2 outbreak: diagnosis, infection prevention, and public perception. Clin Chem. 2020; 66 (5):644â€“651. doi: 10.1093/clinchem/hvaa080.
3. Chen W, Zheng KI, Liu S, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19:18. doi: 10.1186/s12941-020-00362-2.
4. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92:856-62. doi: 10.1002/jmv.25871.
5. Feng Z, Yu Q, Yao S, et al. Early prediction of disease progression in 2019 novel coronavirus pneumonia patients outside Wuhan with CT and clinical characteristics. BMJ. 2020; 36:8. doi.org/10.1101/2020.02.19.20025296.
6. Yufei Y, Mingli L, Xuejiao L, et al. Utility of the neutrophil-to-lymphocyte ratio and Creactive protein level for coronavirus disease 2019 (COVID-19). Scand J Clin Lab Invest. 2020;14:1-5. doi: 10.1080/00365513.2020.1803587.
7. He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005; 9: 323â€“30. doi: 10.1016/j.ijid.2004.07.014.
8. Forget P, Khalifa C, Defour JP, et al. What is the normal value of the neutrophil-to lymphocyte ratio? BMC Res Notes. 2017; 10: 12. doi: 10.1186/s13104-016-2335-5.
9. Khourssaji M, Chapelle V, Evenepoel A, et al. A biological profile for diagnosis and outcome of COVID-19 patients. Clin Chem Lab Med. 2020; 58(12): 2141-2150. doi: 10.1515/cclm-2020-0626 PMID: 33064667.
10. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression, Critical Reviews in Clinical Laboratory Sciences. 2020; 57(6):389-399. doi: 10.1080/10408363.2020.1770685.